Ironwood Pharmaceuticals Inc (NASDAQ:IRWD) Institutional Investors Sentiment Index Increased in 2019 Q1

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Logo

Sentiment for Ironwood Pharmaceuticals Inc (NASDAQ:IRWD)

Ironwood Pharmaceuticals Inc (NASDAQ:IRWD) institutional sentiment increased to 1.37 in 2019 Q1. Its up 0.30, from 1.07 in 2018Q4. The ratio has improved, as 74 funds increased or opened new holdings, while 54 reduced and sold holdings in Ironwood Pharmaceuticals Inc. The funds in our partner’s database now hold: 146.70 million shares, up from 140.64 million shares in 2018Q4. Also, the number of funds holding Ironwood Pharmaceuticals Inc in their top 10 holdings increased from 2 to 3 for an increase of 1. Sold All: 16 Reduced: 38 Increased: 44 New Position: 30.

Ironwood Pharmaceuticals, Inc., a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company has market cap of $1.40 billion. The firm markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States and Constella name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout under ZURAMPIC and DUZALLO names. It currently has negative earnings. It has collaboration agreements with Allergan plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in North America, China, Hong Kong, and Macau; and license agreement with Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, chronic constipation, and other GI conditions in Japan.

The stock decreased 1.64% or $0.15 during the last trading session, reaching $8.97. About 1.27M shares traded. Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has declined 32.56% since August 15, 2018 and is downtrending. It has underperformed by 32.56% the S&P500.

Sarissa Capital Management Lp holds 15.36% of its portfolio in Ironwood Pharmaceuticals, Inc. for 7.54 million shares. Ecor1 Capital Llc owns 4.40 million shares or 5.48% of their US portfolio. Moreover, Bridger Management Llc has 4.48% invested in the company for 4.18 million shares. The Maryland-based Brown Capital Management Llc has invested 1.41% in the stock. Broderick Brian C, a Massachusetts-based fund reported 329,233 shares.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Ratings Coverage

Ratings analysis reveals 25% of Ironwood Pharma’s analysts are positive. Out of 4 Wall Street analysts rating Ironwood Pharma, 1 give it “Buy”, 0 “Sell” rating, while 3 recommend “Hold”. The lowest target is $13 while the high is $18. The stock’s average target of $15.25 is 70.01% above today’s ($8.97) share price. IRWD was included in 8 notes of analysts from February 22, 2019. The stock of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) earned “Buy” rating by Mizuho on Friday, February 22. Morgan Stanley upgraded Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) on Wednesday, March 27 to “Equal-Weight” rating. The firm earned “Hold” rating on Friday, March 22 by Credit Suisse. On Monday, June 24 the stock rating was maintained by H.C. Wainwright with “Hold”. H.C. Wainwright upgraded Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) on Monday, February 25 to “Neutral” rating.

More notable recent Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) news were published by: which released: “Ironwood Pharmaceuticals to Establish New Headquarters in Downtown Boston – Business Wire” on June 13, 2019, also with their article: “Ironwood Pharmaceuticals Completes Separation of Cyclerion Therapeutics and Becomes a Gastrointestinal (GI)-focused Healthcare Company – Business Wire” published on April 01, 2019, published: “Ironwood Pharmaceuticals and Allergan Initiate Patient Dosing in Phase II Clinical Trial of MD-7246 in Patients with Abdominal Pain Associated with IBS-D – Business Wire” on June 03, 2019. More interesting news about Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) were released by: and their article: “Ironwood to Get New CEO, Current CEO to Head Latest Spinoff – Nasdaq” published on January 07, 2019 as well as‘s news article titled: “Ironwood Pharmaceuticals Q4 2018 Earnings Preview – Seeking Alpha” with publication date: February 12, 2019.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.